Proactive Investors - Run By Investors For Investors

Genedrive partners with FIND to evaluate Hepatitis C diagnostic kit in Cameroon and Georgia

Under the agreement, FIND will lead evaluation studies between September 2018 and May 2019 to confirm the accuracy of Genedrive’s HCV kit across diverse genotypes
Hepatitis C
The studies will also evaluate the kit's usability in its intended markets

Genedrive PLC (LON:GDR) has partnered with the Foundation for Innovation of New Diagnostics (FIND) in a study agreement to evaluate its hepatitis C virus (HCV) identification kit.

The AIM-listed biotechnology firm said under the agreement, FIND would lead evaluation studies in Cameroon and Georgia between September 2018 and May 2019 to confirm the accuracy of Genedrive’s HCV kit across diverse genotypes, as well as its usability in the intended market of low-resource areas.

READ: Genedrive shares push higher as the rapid diagnostics specialist gears up for important year

The company added that FIND’s evaluations would feed into the organisation’s broader efforts as part of a multi-year, multi-country HCV project funded by Unitaid to support the development of simple HCV diagnostic tools for use at the point of care.

David Budd, Genedrive’s chief executive, said positive outcomes of the study would facilitate the company’s commercialisation activities in the relevant regions, while also “providing important clinical field data that others look to as they decide to implement [the Genedrive diagnostics platform] in their own specific settings."

View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

1550834286_shutterstock_651647128.jpg
February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use
rasuvo
May 30 2019
The Toronto-based company’s leading products are Rasuvo and Metoject, a unique formulation of methotrexate that is designed to treat rheumatoid arthritis and other auto-immune diseases
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use